Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford

06.01.26 10:34 Uhr

Werte in diesem Artikel
Aktien

945,90 EUR 38,60 EUR 4,25%

Indizes

PKT PKT

18.809,4 PKT 136,9 PKT 0,73%

3.468,9 PKT 16,2 PKT 0,47%

6.954,2 PKT 9,3 PKT 0,13%

For Immediate ReleaseChicago, IL – January 6, 2026 – Today, Zacks Investment Ideas feature highlights Pagaya Technologies Ltd. PGY, Eli Lilly LLY and Weatherford International WFRD.3 Top-Ranked Stocks to Buy in 2026As we enter a new year, the opportunity set in the stock market remains compelling. The US economy has proven more resilient than many expected, the artificial intelligence boom continues to gain momentum, and the rally in equities is broadening beyond the narrow leadership of the Magnificent Seven. Together, these dynamics are creating fertile ground for stock selection as we look ahead to 2026.One tool that has consistently stood out in this environment is the Zacks Rank. It remains one of the most effective investing systems available, with a strong track record of identifying emerging leaders before their stories become consensus. In recent years, I have watched it flag major winners such as Nvidia, Palantir Technologies, and AppLovin well ahead of widespread Wall Street recognition.Today, three stocks in particular rise to the top of the list: Pagaya Technologies Ltd., Eli Lilly and Weatherford International. Each carries a top Zacks Rank, is backed by strong growth expectations, and offers an attractive valuation profile as we move into the next phase of the market cycle.Eli Lilly: Structural Winner, Stock Breaking Out AgainEli Lilly delivered exceptional performance in 2023 and 2024 following the breakthrough adoption of GLP-1 weight-loss therapies, but the stock lost momentum during the first half of 2025 as expectations reset. That pause proved temporary. From late summer through year end, shares staged a powerful advance as sentiment improved, positioning remained relatively light, and healthcare leadership emerged amid rising market volatility. That late year surge appears to have laid the groundwork for another leg higher.Fundamentally, the story continues to strengthen. Eli Lilly was recently upgraded to a Zacks Rank #1 (Strong Buy), reflecting upward revisions to earnings estimates. Valuation remains compelling when viewed against the company’s growth profile. The stock currently trades at 32.2x forward earnings, while EPS is projected to grow at a 41.4% annualized rate over the next three to five years. On the top line, sales are expected to increase 42% this year and a further 22% next year.The technical setup reinforces the bullish case. After forming a broad consolidation during the first half of last year, LLY broke decisively above prior resistance. More recently, the stock has been digesting those gains through a tighter consolidation, consistent with a continuation or bull flag pattern. While shares are pulling back today, they remain well within the current range. A renewed breakout above this structure, particularly above the ~$1,100 level, would likely signal the next phase of the stock’s advance.Pagaya Technologies Ltd: Shares Are on SalePagaya Technologies Ltd. is an emerging fintech player in the “buy now, pay later” (BNPL) space with a compelling risk-reward profile. I first highlighted the stock early last summer when it carried a top Zacks Rank, strong growth projections, an attractive valuation, and improving momentum. The subsequent move exceeded even my expectations, with shares more than tripling in just a few months. That rally was followed by a sharp reset, however, as the stock pulled back more than 50% during the fourth quarter.Today, the setup is once again appealing. Pagaya has returned to a Zacks Rank #1 (Strong Buy), continues to trade at a discounted valuation, and remains backed by robust growth forecasts. Shares change hands at just 6.5x forward earnings, while sales are expected to grow 28.4% this year and 19.2% next year. Earnings growth is even more striking, with estimates calling for a 274% jump this year.Momentum is also starting to turn back in the stock’s favor. Following the sharp correction, PGY spent several weeks consolidating near its recent lows, carving out a base. More recently, shares have broken out of a descending wedge pattern, signaling renewed buying interest to start the year. This early-year breakout looks like a potential pivot point, and as long as the stock holds above that level, the conditions appear favorable for investors to rotate back into the name.Weatherford International: Top Energy Stock Amid Rising Global TensionsWeatherford International shares are trading sharply higher today alongside the broader energy sector, following the Trump administration’s military extraction of former Venezuelan leader Nicolás Maduro. The operation represents a significant geopolitical development, with immediate implications for global energy markets given Venezuela’s position as the holder of the world’s largest proven oil reserves.While the ultimate trajectory of this highly complex situation remains uncertain, the market’s reaction is notable. Energy equities are clearly responding to the perceived shift in risk dynamics. Importantly, Weatherford’s strength is not solely a function of today’s headlines. The stock has carried a top Zacks Rank for several weeks, and the energy sector had already begun to show signs of renewed leadership ahead of this event.From a technical perspective, WFRD had been trending higher through the fourth quarter and spent recent weeks forming a well-defined bull flag. Today’s session marks a decisive breakout from that consolidation. Although sharp, gap-driven moves can feel uncomfortable to chase, they often serve as the early stages of more sustained advances. With energy emerging as a leading sector late last year and oil prices appearing to have established a floor, this breakout reinforces the bullish thesis for both Weatherford and the broader energy space.Should Investors Buy Shares in WFRD, LLY and PGY?Each of these stocks offers a distinct way to participate in the 2026 opportunity set. Eli Lilly represents a quality, structural growth leader with improving momentum. Pagaya offers a beaten down, high-upside growth story with valuation and earnings leverage. Weatherford provides exposure to a resurgent energy cycle amid shifting global dynamics. With all three carrying top Zacks Ranks and supportive fundamental and technical backdrops, they stand out as compelling candidates for investors looking to position within some of the primary market trends.Free: Instant Access to Zacks' Market-Crushing StrategiesSince 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.Get all the details here >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Just Released: Zacks Top 10 Stocks for 2026Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Weatherford International PLC (WFRD): Free Stock Analysis Report Pagaya Technologies Ltd. (PGY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Eli Lilly und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Eli Lilly

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Eli Lilly

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Eli Lilly

Wer­bung

Analysen zu Eli Lilly

DatumRatingAnalyst
20.12.2024Eli Lilly BuyJefferies & Company Inc.
31.10.2024Eli Lilly BuyJefferies & Company Inc.
13.02.2024Eli Lilly and BuyJefferies & Company Inc.
05.10.2018Eli Lilly and OutperformBMO Capital Markets
25.07.2018Eli Lilly and NeutralGoldman Sachs Group Inc.
DatumRatingAnalyst
20.12.2024Eli Lilly BuyJefferies & Company Inc.
31.10.2024Eli Lilly BuyJefferies & Company Inc.
13.02.2024Eli Lilly and BuyJefferies & Company Inc.
05.10.2018Eli Lilly and OutperformBMO Capital Markets
08.06.2018Eli Lilly and OverweightCantor Fitzgerald
DatumRatingAnalyst
25.07.2018Eli Lilly and NeutralGoldman Sachs Group Inc.
27.04.2017Eli Lilly and HoldArgus Research Company
20.03.2017Eli Lilly and NeutralUBS AG
22.07.2015Eli Lilly and Equal WeightBarclays Capital
08.01.2015Eli Lilly and HoldDeutsche Bank AG
DatumRatingAnalyst
21.04.2017Eli Lilly and UnderperformBMO Capital Markets
15.10.2012Eli Lilly and underperformJefferies & Company Inc.
30.06.2010Eli Lilly ErsteinschätzungSoleil Securities Group, Inc.
14.12.2009Eli Lilly sellGoldman Sachs Group Inc.
02.12.2009Eli Lilly sellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Eli Lilly nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen